You are in: eMedicine Specialties > Emergency Medicine > Toxicology
|
Toxicity, Nitrous Dioxide Last Updated: December 7, 2005 |
|
| Synonyms and related keywords: NO2, nitrous dioxide toxicity, nitrous dioxide poisoning, nitrogen dioxide poisoning, nitrogen dioxide toxicity, nitrogen dioxide, nitric oxide, nitrogen tetroxide, nitrous acid, NO2 exposure, nitrogen dioxide exposure, nitrous dioxide exposure, combustion-produced NO2
|
|   |
AUTHOR INFORMATION
| Section 1 of 11  |
|
| Author: Jeffrey S Peterson, MD, Clinical Instructor of Surgery, Department of Emergency Medicine, Stanford University Coauthor(s): Suzanne M Miller, MD, Senior Resident, Department of Emergency Medicine, Stanford Hospital and Clinics; Charles B Cairns, MD, Consulting Staff, Department of Surgery, Division of Emergency Medicine, Duke University Medical Center |
| Jeffrey S Peterson, MD, is a member of the following medical societies:
American Academy of Emergency Medicine,
American College of Emergency Physicians, and
American College of Sports Medicine |
| Editor(s): Miguel C Fernandez, MD, FACEP, FAAEM, FACMT, Associate Clinical Professor; Medical and Managing Director, South Texas Poison Center, Department of Surgery/Emergency Medicine and Toxicology, University of Texas Health Science Center at San Antonio; John T VanDeVoort, PharmD, Clinical Assistant Professor, College of Pharmacy, University of Minnesota;
Fred Harchelroad, MD, FACMT, Chair, Department of Emergency Medicine, Director of Medical Toxicology, Associate Professor, Department of Emergency Medicine, Allegheny General Hospital;
John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School;
and Raymond J Roberge, MD, MPH, FAAEM, FACMT, Clinical Associate Professor of Emergency Medicine, University of Pittsburgh School of Medicine; Consulting Staff, Department of Emergency Medicine, Magee-Women's Hospital of the University of Pittsburgh Medical Center |
Disclosure
|   |
INTRODUCTION
| Section 2 of 11  |
|
Background: Nitrogen dioxide (NO2) is a brownish gas that is produced primarily as a byproduct of high-temperature combustion.
- The American Chemical Society's Chemical Abstract Service (CAS) registry number for nitrogen dioxide is CAS #10102-44-0.
- The United Nations/Department of Transportation number for nitrogen dioxide is UN#1067.
- The National Institute of Occupational Safety and Health (NIOSH) Registry of Toxic Effects of Chemical Substances (RTECS) identifier for nitrogen dioxide is QW 9800000.
Workers are exposed to combustion-produced NO2 in a variety of occupations, including arc welders, firefighters, military and aerospace personnel, and those working with explosives. Nitric oxide (NO), NO2 and other oxides of nitrogen are formed from nitrogen and oxygen during high-temperature combustion. Nitric oxide is oxidized to NO2, a precursor of ozone (O3). Nitric oxide, nitrogen dioxide, and nitrogen tetroxide (N2O4) almost always occur together; hence, the terms oxides of nitrogen and nitrogen oxides are used in literature to refer to these molecules. The term NOX is used most often in air pollution literature in reference to the oxides of nitrogen.
Nitrogen dioxide toxicity is also observed in environments where NO2 is formed from noncombustion sources. These include silo fillers, where nitrogen oxides are a byproduct of anaerobic fermentation of crops, and indoor ice skating rinks, where the gas is generated by the propane-driven ice cleaning machine, the Zamboni. In addition, NO2 from automobile exhaust smokestack emissions are thought to be a major contributor to the toxic effects of air pollution.
Nitrogen dioxide is a deep lung irritant that can produce pulmonary edema and fatality if inhaled at high concentrations. The effects of NO2 depend on the level and duration of exposure. Exposure to moderate NO2 levels (50 ppm) may produce cough, hemoptysis, dyspnea, and chest pain. Exposure to higher concentrations of NO2 (>100 ppm) can produce pulmonary edema that may be fatal or may lead to bronchiolitis obliterans. Some studies suggest that chronic exposure to nitrogen dioxide may predispose individuals to the development of chronic lung diseases, including infection and chronic obstructive pulmonary diseases.
Recent literature on NO2 focuses on its association with nitrous acid (HONO), a molecule that can be formed as a primary product of gas combustion or by the reaction of NO2 with surface water. Although early data are inconclusive, some studies suggest HONO may contribute to the adverse health outcomes previously attributed to NO2. The theoretical health risks of HONO include damage to the mucous membranes and lungs by direct contact with the acid, creation of the carcinogenic nitrosamines secondary to HONO combination with amines, and oxygen free radical production through HONO photolysis in air. However, further studies are needed to tease out the differential effects of NO2 and HONO.
Pathophysiology: The primary locus of NO2 toxicity is the lung. Exposure to NO2 induces pulmonary injury in a number of ways. Nitrogen dioxide is converted to NO, HNO3 (nitric acid), and HNO2 (nitrous acid) in the distal airways, where it exerts direct toxic effects on type I pneumocytes and ciliated airway cells. Nitrogen dioxide initiates free radical generation in the terminal bronchioles, resulting in protein oxidation, lipid peroxidation, and subsequent cell membrane damage. Nitrogen dioxide also alters macrophage and immune function, causing impaired resistance to infection.
Methemoglobinemia also may be induced with the inhalation of NO2 because NO is absorbed through the lungs and binds to hemoglobin, forming nitrosyl hemoglobin. NO has an affinity for hemoglobin that is several thousand times greater than that of carbon monoxide. This complex is readily oxidized to methemoglobin. Methemoglobinemia serves to compound the preexisting hypoxemia by causing a leftward shift of the oxygen-hemoglobin dissociation curve and further impairing tissue oxygenation. Nitric oxide is synthesized endogenously from L-arginine by numerous cell types and has multiple physiologic roles. Frequency:
- In the US: Limited data exist in the United States and worldwide concerning the true prevalence of NO2 exposure and its contribution to morbidity and mortality. The multiple gases and particulates that comprise pollution and the spontaneous conversion of NO2 to other oxides make epidemiological studies difficult.
Mortality/Morbidity: Nitrogen dioxide poisoning may result in mortality or short-term and long-term morbidity. Manifestations of nitrogen dioxide toxicity are related to the concentration inhaled, duration of exposure, and time since exposure.
Race: No epidemiologic studies have indicated that predilection to exposure or to the manifestations of exposure is attributable to race.
Sex: Historically, males are afflicted with the pulmonary sequelae more frequently than females because of their increased numbers in the predisposed occupations. However, no difference in physiologic response appears to be attributable to sex.
|   |
CLINICAL
| Section 3 of 11  |
|
History: The diagnosis of nitrogen dioxide toxicity depends largely on the history of exposure. Query patients on this history if possible. - Inquire about exposure and occupation. Welders, firefighters, military and aerospace personnel, individuals working with explosives, and farmers generally have higher risk of exposure than those in other occupations.
- Try to establish duration of exposure.
- Acute exposure - Symptoms may range from mild cough to mucous membrane irritation to sudden fatality.
- Suspect methemoglobin in patients exposed to nitrogen dioxide gas who exhibit cyanosis or dyspnea.
- The initial absence of significant symptoms does not exclude a subsequent development of serious disease.
- Latency period - Following a delay of 2-48 hours, patients exposed to nitrogen dioxide may develop the following symptoms:
- Clinical manifestations of noncardiogenic pulmonary edema
- Late sequelae - The following may develop 2-6 weeks after initial nitrogen dioxide exposure:
- Bronchiolitis obliterans, manifested as fever, cough, and dyspnea
- Diffuse reticulonodular or miliary pattern on chest x-ray
Physical: Initial physical findings are sometimes mild but may progress over the following 72 hours to life-threatening respiratory distress. - Pulmonary symptoms are the most common manifestation of nitrogen dioxide toxicity.
- Irritation of mucous membranes, including the eyes
- Conjunctival infection
- Weakness
- Fatigue
- Nausea
- Abdominal pain
- Skin burns, in cases of liquid nitrogen tetroxide exposure
- Delayed symptoms
- Tachypnea
- Headache
- Fever, chills
- Insomnia
- Myalgias
- Hemoptysis
- Palpitations
- Cyanosis
- Coma
Causes: - Occupational risk factors for nitrogen dioxide are high among farmers, particularly those who work near silos, firefighters, arc welders, military personnel, and aerospace workers (missile fuel). Any occupation that involves the production, transportation, or use of nitric acid is at risk.
- Other significant sources of risk are ice arenas with ice resurfacing (Zamboni) machines. Gas- and kerosene-fired household appliances as well as motor vehicle exhaust all pose significant risk of exposure.
|   |
DIFFERENTIALS
| Section 4 of 11  |
|
Acute Coronary Syndrome Acute Respiratory Distress Syndrome Chronic Obstructive Pulmonary Disease and Emphysema Congestive Heart Failure and Pulmonary Edema Conjunctivitis Hantavirus Cardiopulmonary Syndrome Methemoglobinemia Myocardial Infarction Pneumonia, Bacterial
Pneumonia, Mycoplasma Pneumonia, Viral Pulmonary Embolism Respiratory Distress Syndrome, Adult Smoke Inhalation Toxicity, Carbon Monoxide Toxicity, Chlorine Gas Toxicity, Hydrogen Sulfide Toxicity, Organophosphate and Carbamate
Toxicity, Phosgene Toxicity, Salicylate
|
| Related Articles | Acute Coronary Syndrome
Acute Respiratory Distress Syndrome
Chronic Obstructive Pulmonary Disease and Emphysema
Congestive Heart Failure and Pulmonary Edema
Conjunctivitis
Hantavirus Cardiopulmonary Syndrome
Methemoglobinemia
Myocardial Infarction
Pneumonia, Bacterial
Pneumonia, Mycoplasma
Pneumonia, Viral
Pulmonary Embolism
Respiratory Distress Syndrome, Adult
Smoke Inhalation
Toxicity, Carbon
Monoxide
Toxicity, Chlorine Gas
Toxicity, Hydrogen Sulfide
Toxicity, Organophosphate and Carbamate
Toxicity, Phosgene
Toxicity, Salicylate
|
|
Patient Education
|
|
Click here for patient education.
|
|
|
|
|
|   |
WORKUP
| Section 5 of 11  |
|
Lab Studies:
- No laboratory studies that are specific to nitrogen dioxide–induced illness have been reported.
- Pulmonary function tests, if obtained late in the clinical course when bronchiolitis obliterans has developed, demonstrate presence of restrictive and obstructive disease.
- Following a significant exposure, arterial blood gases (ABGs) usually reveal hypoxemia.
- Methemoglobin levels may be increased after exposure to NO2. Although methemoglobin levels as high as 71% have been reported following exposure to nitrous fumes, welders exposed to nitrogen dioxide at 4-5 ppm were noted to have methemoglobin levels of 2-3%.
- Obtain a complete blood count (CBC) with a peripheral smear and examine it for indications of hemolysis.
- Measure glucose levels to assure that anxiety and restlessness is not caused by concomitant hypoglycemia; however, exposure to nitrogen dioxide does not cause a primary hypoglycemia.
Imaging Studies:
- Chest x-ray findings range from normal to noncardiogenic pulmonary edema to that of soft reticulonodular infiltrates.
|   |
TREATMENT
| Section 6 of 11  |
|
Prehospital Care: - Direct prehospital care towards stabilization of pulmonary function. These actions should include removal of the patient from the source of exposure, provision of supplemental oxygen, and, if needed, airway management and ventilatory support.
- Be aware of the risk of exposure when treating patients and wear a self-contained breathing apparatus (SCBA), when indicated.
Emergency Department Care: - The primary treatment of NO2-induced respiratory illness is supportive therapy directed at correction of hypoxemia, ventilatory failure, and secondary infection.
- Endotracheal intubation and mechanical ventilation may be required, depending on the clinical degree of respiratory distress and hypoxemia.
- High-dose corticosteroids are suggested in the treatment of pulmonary manifestations, but data on their prophylactic use after NO2 exposure is anecdotal.
- Most authors agree that patients with bronchiolitis obliterans should be maintained on corticosteroids until their symptoms have resolved.
Consultations: - Consult with a regional poison control center or a local medical toxicologist (certified through the American Board of Medical Toxicology and/or the American Board of Emergency Medicine) to obtain additional information and patient care recommendations.
- Prolonged critical care management is often required for the pulmonary complications of those patients who require endotracheal intubation.
|   |
MEDICATION
| Section 7 of 11  |
|
High-dose corticosteroids are suggested in the treatment of pulmonary manifestations, but data on their prophylactic use after NO2 exposure are anecdotal.
Drug Category: Corticosteroids -- These agents reduce the inflammatory response. Whether early administration can prevent development of noncardiogenic pulmonary edema is unknown. The decision to administer corticosteroids must be made on clinical grounds. Drug Name
| Methylprednisolone (Solu-Medrol) -- Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Consider tapering if prolonged dosing (>14 d) is required.| Adult Dose | 125 mg IV initial; repeat prn; not to exceed 30 mg/kg/dose |
|---|
| Pediatric Dose | 2-5 mg/kg IV initial; repeat prn; not to exceed 30 mg/kg/dose |
|---|
| Contraindications | Documented hypersensitivity; viral, fungal, or tubercular skin infections |
|---|
| Interactions | Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels of methylprednisolone; phenobarbital, phenytoin, and rifampin may decrease levels of methylprednisolone (adjust dose); monitor patients for hypokalemia when taking medication concurrently with diuretics |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections are possible complications of glucocorticoid use |
|---|
| Drug Category: Antidotes -- Methylene blue, which is tetramethyl thionine chloride, is the recommended antidote for methemoglobinemia. It is reduced to leukomethylene blue, which is then available to reduce methemoglobin to hemoglobin.Drug Name
| Methylene blue -- DOC if patient is cyanotic from methemoglobinemia and symptomatic or if methemoglobin level is >30%. Alters pulse oximetry readings. Available as 1% solution (10 mg/mL) in 10 mL ampules. |
|---|
| Adult Dose | 1-2 mg/kg IV over 5 min |
|---|
| Pediatric Dose | Neonates: 0.3-1 mg/kg IV over 5 min >30 days: Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity; renal insufficiency |
|---|
| Interactions | None reported |
|---|
| Pregnancy |
C - Safety for use during pregnancy has not been established.
|
|---|
| Precautions | Can cause profound anemia in G-6-PD deficiency; high doses (5-10 mg/kg) or rapid IV administration may induce acute hemolytic anemia or cause further methemoglobin production; do not inject into CNS |
|---|
|   |
FOLLOW-UP
| Section 8 of 11  |
|
Further Inpatient Care:
- Patients presenting with hypoxemia, dyspnea, or an altered level of consciousness require observation in the hospital for a minimum of 24 hours.
- Determine discharge decisions based on clinical improvement and resolution of hypoxemia and methemoglobinemia.
- Patients initially asymptomatic following a known exposure should be observed for at least 8 hours for evidence of developing hypoxemia and respiratory failure. Noncardiogenic pulmonary edema may develop slowly over 48 hours after a significant exposure.
Further Outpatient Care:
- Following a known exposure, perform complete pulmonary function tests and clinical evaluations in 3 weeks and again in 3 months.
In/Out Patient Meds:
- Corticosteroids may need to be tapered over a long period (6-12 mo) if serious concern over developing toxic bronchiolitis obliterans exists.
- Inhaled sympathomimetics (eg, albuterol), anticholinergics (eg, ipratropium bromide), and steroids (eg, fluticasone propionate) may be indicated for those who develop a reactive airways dysfunction syndrome (RADS) postexposure.
Deterrence/Prevention:
- Working environments should be evaluated for elevated NO2 levels and proper ventilation and protective gear, such as self-contained breathing apparatus (SCBA), should be used.
- American Conference of Governmental Industrial Hygienists-Threshold Limit Values (ACGIH-TLV): 3 ppm time weighted average (TWA); 5 ppm short-term exposure limit (STEL) (ACGIH,1998)
- The National Institute of Occupational Safety and Health (NIOSH) values: Recommended Exposure Limit (REL) 1 ppm short-term exposure limit (STEL) immediately dangerous to life or health (IDLH) 20 ppm
- Labels required: Poison gas, oxidizer, corrosive
- National Fire Protection Association (NFPA) hazard ratings
- Health (Blue) 3
- Flammability (Red) 0
- Reactivity (Yellow) 0
- Respiratory recommendations - North American Emergency Response Guide (NAERG) 124: Wear positive-pressure SCBA.
- Protective clothing - NAERG 124: Wear chemically protective clothing as recommended by the manufacturer.
Prognosis:
- Overall, the long-term prognosis is good for patients who survive the initial exposure to nitrogen dioxide.
- The long-term prognosis is determined by follow-up pulmonary function evaluation.
Patient Education:
- Advise patients who have had a significant exposure to nitrogen dioxide to avoid other pulmonary toxins. They should wear appropriate personal protective equipment in the workplace.
- Advise patients that delayed symptoms, including life-threatening pulmonary edema and dyspnea caused by bronchiolitis obliterans, may result. Therefore, patients should be followed for a minimum of 2-3 months after exposure to monitor possible development of bronchiolitis obliterans.
|   |
MISCELLANEOUS
| Section 9 of 11  |
|
Medical/Legal Pitfalls:
- Failure to consider the asymptomatic period and delayed onset of symptoms associated with nitrogen dioxide toxicity; discharging the patient from the ED too soon
- Failure to consider nitrogen dioxide toxicity in patients who present with dyspnea and have occupations with risk of exposure
- Failure to recognize early signs of significant respiratory distress and document either pO2 or oxygen saturation via pulse oximetry
- Failure to have the patient monitored in a setting where respiratory support is available immediately
|   |
PICTURES
| Section 10 of 11  |
|
| Caption: Picture 1. Bronchiolitis obliterans following exposure to nitrogen dioxide. (Radiograph courtesy of Dr Ann Leung, Stanford University Hospital, Department of Radiology, Palo Alto, CA) |  | View Full Size Image |
|
Picture Type: X-RAY |
| Caption: Picture 2. Noncardiogenic pulmonary edema following exposure to nitrogen dioxide. (Radiograph courtesy of Dr Ann Leung, Stanford University Hospital, Department of Radiology, Palo Alto, CA) |  | View Full Size Image |
|
Picture Type: X-RAY |
|   |
BIBLIOGRAPHY
| Section 11 of 11 |
|
-
Becker S, Soukup JM: Effect of nitrogen dioxide on respiratory viral infection in airway epithelial cells. Envir Res. 1999; 81(2): 159-66[Medline].
-
Douglas WW, Hepper NG, Colby TV: Silo-filler's disease. Mayo Clin Proc 1989 Mar; 64(3): 291-304[Medline].
-
Elsayed NM: Toxicity of nitrogen dioxide: an introduction. Toxicology 1994 May 20; 89(3): 161-74[Medline].
-
Evans MJ, Stephens RJ, Cabral LJ, Freeman G: Cell renewal in the lungs of rats exposed to low levels of NO2. Arch Environ Health 1972 Mar; 24(3): 180-8[Medline].
-
Hajela R, Janigan DT, Landrigan PL, et al: Fatal pulmonary edema due to nitric acid fume inhalation in three pulp- mill workers. Chest 1990 Feb; 97(2): 487-9[Medline].
-
Hedberg K, Hedberg CW, Iber C, et al: An outbreak of nitrogen dioxide-induced respiratory illness among ice hockey players. JAMA 1989 Dec 1; 262(21): 3014-7[Medline].
-
Horowitz RS: Nitrogen oxides and silo-filler's disease. In: Viccellio P, Bania T, eds. Emergency Toxicology. 2nd ed. Lippincott Williams & Wilkins; 1998:959-64.
-
Jarvis DL, Leaderer BP, Chinn S, Burney PG: Indoor nitrous acid and respiratory symptoms and lung function in adults. Thorax 2005 Jun; 60(6): 474-9[Medline].
-
Jones GR, Proudfoot AT, Hall JI: Pulmonary effects of acute exposure to nitrous fumes. Thorax 1973 Jan; 28(1): 61-5[Medline].
-
Lee K, Xue J, Geyh AS, et al: Nitrous acid, nitrogen dioxide, and ozone concentrations in residential environments. Environ Health Perspect 2002 Feb; 110(2): 145-50[Medline].
-
Mayorga MA: Overview of nitrogen dioxide effects on the lung with emphasis on military relevance. Toxicology 1994 May 20; 89(3): 175-92[Medline].
-
Papi A, Amadesi S, Chitano P, et al: Bronchopulmonary inflammation and airway smooth muscle hyperresponsiveness induced by nitrogen dioxide in guinea pigs. Eur J Pharmacol 1999 Jun 18; 374(2): 241-7[Medline].
-
Prutz WA, Monig H, Butler J, Land EJ: Reactions of nitrogen dioxide in aqueous model systems: oxidation of tyrosine units in peptides and proteins. Arch Biochem Biophys 1985 Nov 15; 243(1): 125-34[Medline].
-
Sagai M, Ichinose T: Lipid peroxidation and antioxidative protection mechanism in rat lungs upon acute and chronic exposure to nitrogen dioxide. Environ Health Perspect 1987 Aug; 73: 179-89[Medline].
-
van Bree L, Rietjens I, Alink GM, et al: Biochemical and morphological changes in lung tissue and isolated lung cells of rats induced by short-term nitrogen dioxide exposure. Hum Exp Toxicol 2000 Jul; 19(7): 392-401[Medline].
-
van Strien RT, Gent JF, Belanger K, et al: Exposure to NO2 and nitrous acid and respiratory symptoms in the first year of life. Epidemiology 2004 Jul; 15(4): 471-8[Medline].
-
Veeramachaneni NK, Harken AH, Cairns CB: Clinical implications of hemoglobin as a nitric oxide carrier. Arch Surg 1999 Apr; 134(4): 434-7[Medline].
-
Weller BL, Witschi H, Pinkerton KE: Quantitation and localization of pulmonary manganese superoxide dismutase and tumor necrosis factor alpha following exposure to ozone and nitrogen dioxide. Toxicol Sci 2000 Apr; 54(2): 452-61[Medline].
-
World Health Organization: Nitrogen oxides. In: Recommended Health-Based Occupation Exposure Limits for Respiratory Irritants. 1984:73-114.
Toxicity, Nitrous Dioxide excerpt |